At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 63 enrolled
Drug / intervention
Pristiq +1 moredrug
Likely dose
Pristiq 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder
In Brief
A Phase 4 clinical trial evaluating Pristiq and Placebo for Social Anxiety Disorder. Completed, enrolled 63 participants across 1 site.
Detailed Summary
This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSocial Anxiety Disorder
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartApr 2011
Primary CompletionNov 2012
Study CompletionDec 2012
TodayJul 2026
First PostedMar 16, 2011
Enrollment StartApr 1, 2011
Primary CompletionNov 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.3 years ago
Interventions
Pristiqdrug
Flexible dose, 50-100mg QD, for 12 weeks.
Placebodrug
Matching placebo, taken QD for 12 weeks.